{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:39:20Z","timestamp":1793209160307,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","award":["Y202044796"],"award-info":[{"award-number":["Y202044796"]}],"id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2014\\u201306-2103"],"award-info":[{"award-number":["Z-2014\\u201306-2103"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2020\\u201301-16"],"award-info":[{"award-number":["320.6750.2020\\u201301-16"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.intimp.2021.108469","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T15:39:30Z","timestamp":1641569970000},"page":"108469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"special_numbering":"C","title":["Immunotherapy of Cancer by Targeting Regulatory T cells"],"prefix":"10.1016","volume":"104","author":[{"given":"Bo-Jin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Wen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-5957","authenticated-orcid":false,"given":"Guo-Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2021.108469_b0005","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","article-title":"Regulatory T cells in tumor immunity","volume":"127","author":"Nishikawa","year":"2010","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2021.108469_b0010","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10753-012-9496-8","article-title":"CD4(+)CD25 (+)CD127 (low\/-) T cells: a more specific Treg population in human peripheral blood","volume":"35","author":"Yu","year":"2012","journal-title":"Inflammation"},{"issue":"2","key":"10.1016\/j.intimp.2021.108469_b0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni759","article-title":"Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance","volume":"3","author":"Shimizu","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.intimp.2021.108469_b0020","first-page":"1","article-title":"Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice","volume":"2","author":"Jones","year":"2002","journal-title":"Cancer Immun"},{"issue":"3","key":"10.1016\/j.intimp.2021.108469_b0025","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0952-7915(93)90056-X","article-title":"Antigen-presenting cell types","volume":"5","author":"Knight","year":"1993","journal-title":"Curr Opin Immunol"},{"issue":"23","key":"10.1016\/j.intimp.2021.108469_b0030","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1073\/pnas.1508224112","article-title":"Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans","volume":"112","author":"Miyara","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7169","key":"10.1016\/j.intimp.2021.108469_b0035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2021.108469_b0040","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.3389\/fimmu.2018.02374","article-title":"Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression","volume":"9","author":"Gianchecchi","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0045","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41467-019-11280-z","article-title":"Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1","volume":"10","author":"Leclerc","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0050","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1873607","article-title":"Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer","volume":"10","author":"Martinez","year":"2021","journal-title":"Oncoimmunology"},{"issue":"19","key":"10.1016\/j.intimp.2021.108469_b0055","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.intimp.2021.108469_b0060","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","article-title":"Blockade of TIGIT\/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.intimp.2021.108469_b0065","doi-asserted-by":"crossref","first-page":"101305","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin Immunol"},{"issue":"12","key":"10.1016\/j.intimp.2021.108469_b0070","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.intimp.2021.108469_b0075","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.intimp.2021.108469_b0080","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cancers13020282","article-title":"The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3","volume":"13","author":"Marcq","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.intimp.2021.108469_b0085","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41422-018-0011-0","article-title":"A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/nnm-2019-0190","article-title":"Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy","volume":"15","author":"Chen","year":"2020","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.intimp.2021.108469_b0095","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fimmu.2020.00634","article-title":"IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses","volume":"11","author":"Qu","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0100","first-page":"1371","article-title":"Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15\/IL15R\u03b1 Complexes Enhances Tumor Control. Cancer","volume":"7","author":"Sanseviero","year":"2019","journal-title":"Immunol Res"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","article-title":"Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy","volume":"41","author":"Liu","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"200","key":"10.1016\/j.intimp.2021.108469_b0110","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.intimp.2021.108469_b0115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1078-0432.CCR-14-1187","article-title":"Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer","volume":"21","author":"Anagnostou","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40425-018-0493-9","article-title":"alpha-PD-1 therapy elevates Treg\/Th balance and increases tumor cell pSmad3 that are both targeted by alpha-TGFbeta antibody to promote durable rejection and immunity in squamous cell carcinomas","volume":"7","author":"Dodagatta-Marri","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.intimp.2021.108469_b0125","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.2147\/OTT.S221340","article-title":"The Role Of PD-1\/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy","volume":"12","author":"Cai","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"13","key":"10.1016\/j.intimp.2021.108469_b0130","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.intimp.2021.108469_b0135","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1245\/s10434-018-07117-6","article-title":"MiR-21 Participates in the PD-1\/PD-L1 Pathway-Mediated Imbalance of Th17\/Treg Cells in Patients After Gastric Cancer Resection","volume":"26","author":"Zheng","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"10.1016\/j.intimp.2021.108469_b0140","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.1016\/j.intimp.2021.108469_b0145","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1182\/blood-2013-02-481788","article-title":"Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells","volume":"122","author":"Zhang","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0150","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.4049\/jimmunol.1901413","article-title":"A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects","volume":"205","author":"Yang","year":"2020","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.intimp.2021.108469_b0155","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","article-title":"Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II","volume":"180","author":"Liang","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2021.108469_b0160","first-page":"29","article-title":"Overview of LAG-3-Expressing, IL-10-Producing Regulatory T Cells","volume":"410","author":"Fujio","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2021.108469_b0165","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.intimp.2021.108469_b0170","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1158\/1078-0432.CCR-09-0068","article-title":"A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma","volume":"15","author":"Brignone","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.intimp.2021.108469_b0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.intimp.2021.108469_b0180","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/1078-0432.CCR-15-1212","article-title":"Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients-Report of a Phase I\/IIa Clinical Trial","volume":"22","author":"Legat","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.intimp.2021.108469_b0185","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0195","first-page":"3419","article-title":"Preferential Tim-3 expression on Treg and CD8(+) T cells, supported by tumor-associated macrophages, is associated with worse prognosis in gastric cancer","volume":"8","author":"Shen","year":"2016","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-018-0713-7","article-title":"Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer","volume":"37","author":"Liu","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.intimp.2021.108469_b0205","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.ymthe.2017.06.023","article-title":"A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice","volume":"25","author":"Gefen","year":"2017","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.intimp.2021.108469_b0210","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1002\/eji.201343451","article-title":"Modulation of Treg cells\/T effector function by GITR signaling is context-dependent","volume":"43","author":"Ephrem","year":"2013","journal-title":"Eur J Immunol"},{"issue":"408","key":"10.1016\/j.intimp.2021.108469_b0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3085","article-title":"Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant","volume":"9","author":"Tkachev","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.intimp.2021.108469_b0220","doi-asserted-by":"crossref","first-page":"e001687","DOI":"10.1136\/jitc-2020-001687","article-title":"Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy","volume":"8","author":"Jacoberger-Foissac","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.intimp.2021.108469_b0225","doi-asserted-by":"crossref","first-page":"e000738","DOI":"10.1136\/esmoopen-2020-000738","article-title":"New emerging targets in cancer immunotherapy: the role of GITR","volume":"4","author":"Buzzatti","year":"2019","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.intimp.2021.108469_b0230","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/eji.201948393","article-title":"Tumor necrosis factor receptor family costimulation increases regulatory T-cell activation and function via NF-\u03baB","volume":"50","author":"Lubrano di Ricco","year":"2020","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0235","doi-asserted-by":"crossref","first-page":"e000544","DOI":"10.1136\/esmoopen-2019-000544","article-title":"The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy","volume":"5","author":"Solinas","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.intimp.2021.108469_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.06.028","article-title":"Rationale for anti-GITR cancer immunotherapy","volume":"67","author":"Knee","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2021.108469_b0245","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/0008-5472.CAN-16-0797","article-title":"Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy","volume":"77","author":"Mahne","year":"2017","journal-title":"Cancer Res"},{"issue":"589","key":"10.1016\/j.intimp.2021.108469_b0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd9882","article-title":"Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma","volume":"13","author":"Murakami","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0255","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1038\/s41467-021-22885-8","article-title":"Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas","volume":"12","author":"Amoozgar","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2021.108469_b0260","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ijc.32181","article-title":"GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma","volume":"145","author":"Beek","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2021.108469_b0265","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41591-019-0420-8","article-title":"Rational design of anti-GITR-based combination immunotherapy","volume":"25","author":"Zappasodi","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4\u20131BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2021.108469_b0275","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ajh.25757","article-title":"Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma","volume":"95","author":"Timmerman","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0280","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0285","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-17-1922","article-title":"Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB\/CD137 Agonist, in Patients with Advanced Cancer","volume":"24","author":"Segal","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2021.108469_b0290","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.immuni.2018.09.014","article-title":"Antibodies to Costimulatory Receptor 4\u20131BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function","volume":"49","author":"Buchan","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2021.108469_b0295","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI128672","article-title":"A conserved intratumoral regulatory T cell signature identifies 4\u20131BB as a pan-cancer target","volume":"130","author":"Freeman","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2021.108469_b0300","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.4049\/jimmunol.172.6.3580","article-title":"Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells","volume":"172","author":"Takeda","year":"2004","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108469_b0305","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","article-title":"Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity","volume":"10","author":"Fu","year":"2020","journal-title":"Acta. Pharm Sin B"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0310","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41467-021-21383-1","article-title":"Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells","volume":"12","author":"Duhen","year":"2021","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.intimp.2021.108469_b0315","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-19-3070","article-title":"Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors","volume":"26","author":"Glisson","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2021.108469_b0320","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2326-6066.CIR-16-0284","article-title":"A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice","volume":"5","author":"Foote","year":"2017","journal-title":"Cancer Immunol Res."},{"issue":"2","key":"10.1016\/j.intimp.2021.108469_b0325","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2326-6066.CIR-13-0031-T","article-title":"Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity","volume":"2","author":"Redmond","year":"2014","journal-title":"Cancer Immunol Res."},{"issue":"6","key":"10.1016\/j.intimp.2021.108469_b0330","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI64859","article-title":"Depleting tumor-specific Tregs at a single site eradicates disseminated tumors","volume":"123","author":"Marabelle","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.intimp.2021.108469_b0335","doi-asserted-by":"crossref","first-page":"e1494111","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination immune checkpoint blockade as an effective therapy for mesothelioma","volume":"7","author":"Fear","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0340","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-019-0570-8","article-title":"The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation","volume":"7","author":"Kvarnhammar","year":"2019","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.intimp.2021.108469_b0345","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2017.01.006","article-title":"OX40: Structure and function - What questions remain?","volume":"83","author":"Willoughby","year":"2017","journal-title":"Mol. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0350","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.4049\/jimmunol.1300409","article-title":"Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice","volume":"191","author":"He","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.108469_b0355","article-title":"Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice","author":"Wasiuk","year":"2021","journal-title":"Cancer Immunol. Immunother"},{"issue":"10","key":"10.1016\/j.intimp.2021.108469_b0360","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00262-020-02610-y","article-title":"Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy","volume":"69","author":"Vitale","year":"2020","journal-title":"Cancer Immunol. Immunother"},{"issue":"9","key":"10.1016\/j.intimp.2021.108469_b0365","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/bloodadvances.2019001079","article-title":"Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies","volume":"4","author":"Ansell","year":"2020","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.intimp.2021.108469_b0370","doi-asserted-by":"crossref","first-page":"e0239595","DOI":"10.1371\/journal.pone.0239595","article-title":"ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models","volume":"15","author":"Hanson","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2021.108469_b0375","doi-asserted-by":"crossref","first-page":"14340","DOI":"10.1038\/ncomms14340","article-title":"Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity","volume":"8","author":"Zamarin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2021.108469_b0380","doi-asserted-by":"crossref","first-page":"35056","DOI":"10.1038\/srep35056","article-title":"Regulatory T cells, especially ICOS(+) FOXP3(+) regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival","volume":"6","author":"Tu","year":"2016","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2021.108469_b0385","first-page":"1568","article-title":"An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression. Cancer","volume":"8","author":"Sainson","year":"2020","journal-title":"Immunol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2021.108469_b0390","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.20041982","article-title":"Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization","volume":"201","author":"Setoguchi","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.108469_b0395","doi-asserted-by":"crossref","unstructured":"Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'brien T, Nicol D, Challacombe B, Beers SA, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46(4): 577-586.","DOI":"10.1016\/j.immuni.2017.03.013"},{"issue":"7","key":"10.1016\/j.intimp.2021.108469_b0400","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/eji.202049043","article-title":"CCR4 in cutaneous T-cell lymphoma: therapeutic targeting of a pathogenic driver","volume":"51","author":"Nicolay","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.108469_b0405","doi-asserted-by":"crossref","first-page":"e001749","DOI":"10.1136\/jitc-2020-001749","article-title":"Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy","volume":"9","author":"Van Damme","year":"2021","journal-title":"J. Immunother Cancer"},{"issue":"20","key":"10.1016\/j.intimp.2021.108469_b0410","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/1078-0432.CCR-10-1757","article-title":"Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I\/II study in metastatic melanoma patients","volume":"16","author":"Jacobs","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0415","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1073\/pnas.1815087116","article-title":"Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma","volume":"116","author":"Cheung","year":"2019","journal-title":"Proc. Natl. Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0420","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s10120-019-00988-y","article-title":"Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT","volume":"23","author":"Nishimura","year":"2020","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0425","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41598-021-81465-4","article-title":"Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer","volume":"11","author":"Katsube","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0430","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-\u03b2 Signaling in Cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0435","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-019-1967-3","article-title":"Blockade of TGF-\u03b2 signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4(+)CD25(+)Foxp3(+) and CD4(+)CD25(-)Foxp3(+) T cells","volume":"17","author":"Polanczyk","year":"2019","journal-title":"J. Transl. Med."},{"issue":"1 Suppl 3","key":"10.1016\/j.intimp.2021.108469_b0440","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.seminoncol.2005.12.017","article-title":"Clinical experience with denileukin diftitox (ONTAK)","volume":"33","author":"Foss","year":"2006","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.intimp.2021.108469_b0445","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/leu.2011.297","article-title":"Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma","volume":"26","author":"Ansell","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.intimp.2021.108469_b0450","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1158\/1541-7786.MCR-17-0333","article-title":"Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT","volume":"15","author":"Nagaya","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2021.108469_b0455","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.molonc.2016.07.010","article-title":"Near infrared photoimmunotherapy of B-cell lymphoma","volume":"10","author":"Nagaya","year":"2016","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108469_b0460","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1021\/acs.molpharmaceut.0c01107","article-title":"Fluorescence Imaging of Tumor-Accumulating Antibody-IR700 Conjugates Prior to Near-Infrared Photoimmunotherapy (NIR-PIT) Using a Commercially Available Camera Designed for Indocyanine Green","volume":"18","author":"Inagaki","year":"2021","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.intimp.2021.108469_b0465","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1021\/acs.bioconjchem.9b00547","article-title":"The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy","volume":"30","author":"Okada","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.intimp.2021.108469_b0470","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1349-7006.2006.00307.x","article-title":"CCR4 as a novel molecular target for immunotherapy of cancer","volume":"97","author":"Ishida","year":"2006","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.intimp.2021.108469_b0475","doi-asserted-by":"crossref","first-page":"e000764","DOI":"10.1136\/jitc-2020-000764","article-title":"Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4","volume":"8","author":"Marshall","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"15","key":"10.1016\/j.intimp.2021.108469_b0480","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.1021\/acs.jmedchem.0c00988","article-title":"Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors","volume":"63","author":"Robles","year":"2020","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.intimp.2021.108469_b0485","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1021\/acs.jmedchem.9b00506","article-title":"Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment","volume":"62","author":"Jackson","year":"2019","journal-title":"J. Med. Chem."},{"issue":"8_suppl","key":"10.1016\/j.intimp.2021.108469_b0490","doi-asserted-by":"crossref","first-page":"TPS24","DOI":"10.1200\/JCO.2019.37.8_suppl.TPS24","article-title":"Phase I\/II dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer","volume":"37","author":"Ho","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2021.108469_b0495","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.108469_b0500","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2147\/OTT.S165615","article-title":"Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma","volume":"12","author":"Ollila","year":"2019","journal-title":"Onco. Targets Ther."},{"issue":"22","key":"10.1016\/j.intimp.2021.108469_b0505","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","article-title":"A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors","volume":"25","author":"Doi","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2021.108469_b0510","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.intimp.2021.108469_b0515","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00262-020-02583-y","article-title":"CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer","volume":"69","author":"Wang","year":"2020","journal-title":"Cancer Immunol. Immunother"},{"issue":"18","key":"10.1016\/j.intimp.2021.108469_b0520","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1158\/0008-5472.CAN-18-1119","article-title":"Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer","volume":"78","author":"Villarreal","year":"2018","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2021.108469_b0525","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1158\/0008-5472.CAN-20-3585","article-title":"Fc-optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models","volume":"81","author":"Campbell","year":"2021","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2021.108469_b0530","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/imm.13337","article-title":"CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function","volume":"163","author":"Whiteside","year":"2021","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0535","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0540","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.4049\/jimmunol.1301843","article-title":"TGF-\u03b2: guardian of T cell function","volume":"191","author":"Oh","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0545","doi-asserted-by":"crossref","first-page":"18994","DOI":"10.1038\/s41598-020-76130-1","article-title":"Regulatory (FoxP3(+)) T cells and TGF-\u03b2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer","volume":"10","author":"Koh","year":"2020","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.intimp.2021.108469_b0550","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrc1926","article-title":"Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer","volume":"6","author":"Bierie","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2021.108469_b0555","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI89281","article-title":"Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-\u03b2 signaling","volume":"127","author":"Ansa-Addo","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"31","key":"10.1016\/j.intimp.2021.108469_b0560","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1038\/onc.2013.370","article-title":"MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways","volume":"33","author":"Li","year":"2014","journal-title":"Oncogene"},{"issue":"32","key":"10.1016\/j.intimp.2021.108469_b0565","doi-asserted-by":"crossref","first-page":"13445","DOI":"10.1073\/pnas.0901944106","article-title":"GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells","volume":"106","author":"Tran","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"24","key":"10.1016\/j.intimp.2021.108469_b0570","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1158\/0008-5472.CAN-16-1456","article-title":"Surface Expression of TGF\u03b2 Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer","volume":"76","author":"Metelli","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12022-018-9557-0","article-title":"Increased Expression of GARP in Papillary Thyroid Carcinoma","volume":"30","author":"Zhang","year":"2019","journal-title":"Endocr. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0580","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-018-0570-z","article-title":"Immunoregulatory functions and the therapeutic implications of GARP-TGF-\u03b2 in inflammation and cancer","volume":"11","author":"Metelli","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0585","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/intimm\/dxab027","article-title":"Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells","volume":"33","author":"Satoh","year":"2021","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108469_b0595","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3892\/or.2016.4946","article-title":"Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells","volume":"36","author":"Yuan","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2021.108469_b0600","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.intimp.2016.02.015","article-title":"Methionine enkephalin, its role in immunoregulation and cancer therapy","volume":"37","author":"Zhao","year":"2016","journal-title":"Int. Immunopharmacol"},{"issue":"3","key":"10.1016\/j.intimp.2021.108469_b0605","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/15384047.2014.1003006","article-title":"Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice","volume":"16","author":"Li","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2021.108469_b0610","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.4161\/hv.28804","article-title":"Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs)","volume":"10","author":"Wang","year":"2014","journal-title":"Hum. Vaccin. Immunother"},{"issue":"3","key":"10.1016\/j.intimp.2021.108469_b0615","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00001813-200403000-00003","article-title":"Treatment of advanced pancreatic cancer with opioid growth factor: phase I","volume":"15","author":"Smith","year":"2004","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.intimp.2021.108469_b0620","first-page":"37","article-title":"Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer","volume":"2010","author":"Smith","year":"2010","journal-title":"Open Access J. Clin. Trials"},{"issue":"4","key":"10.1016\/j.intimp.2021.108469_b0625","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s10637-012-9918-3","article-title":"Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment","volume":"31","author":"Rogosnitzky","year":"2013","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0630","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","article-title":"The anti-tumour effects of zoledronic acid","volume":"3","author":"Zekri","year":"2014","journal-title":"J. Bone Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0635","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12865-016-0183-7","article-title":"Immune modulation of CD4(+)CD25(+) regulatory T cells by zoledronic acid","volume":"17","author":"Liu","year":"2016","journal-title":"BMC Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0640","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12885-019-5379-9","article-title":"Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2021.108469_b0645","doi-asserted-by":"crossref","first-page":"e1338238","DOI":"10.1080\/2162402X.2017.1338238","article-title":"Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer","volume":"6","author":"Sarhan","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2021.108469_b0650","unstructured":"Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'brien T, M\u00e5rtensson L, Ljungars A, Teige I, Frend\u00e9us B, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell, 2018, 33(4): 649-663.e4."},{"issue":"1","key":"10.1016\/j.intimp.2021.108469_b0655","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4049\/jimmunol.1900575","article-title":"Pembrolizumab Interferes with the Differentiation of Human FOXP3(+)-Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR","volume":"204","author":"Sasidharan Nair","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.108469_b0660","doi-asserted-by":"crossref","first-page":"e000629","DOI":"10.1136\/esmoopen-2019-000629","article-title":"New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)","volume":"4","author":"Starzer","year":"2019","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.intimp.2021.108469_b0665","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.4049\/jimmunol.1700606","article-title":"CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy","volume":"199","author":"Wasiuk","year":"2017","journal-title":"J. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692101105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692101105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:50:41Z","timestamp":1778820641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692101105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":132,"alternative-id":["S156757692101105X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108469","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.170667889.96637484\/v1","asserted-by":"object"}]},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy of Cancer by Targeting Regulatory T cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108469"}}